View source for Organization:Rothberg Institute for Childhood Diseases

{{Infobox nonprofit
| formation = 2002
| founder = Jonathan Rothberg
| type = 501(c)(3)
| headquarters = Guilford, Connecticut
| website = http://www.childhooddiseases.org/
}}
The '''Rothberg Institute For Childhood Diseases''' is a non-profit organization dedicated to finding a cure for rare childhood diseases such as Tuberous Sclerosis Complex (TSC). The organization was founded by Jonathan Rothberg and his wife in 2002 after their son was born with TSC.<ref>{{cite web |url=http://yalemedicine.yale.edu/ym_wi07/faces.html |title=Yale Medicine Winter 2007: Alumni |accessdate=2016-11-14 |url-status=dead |archiveurl=https://web.archive.org/web/20070509143429/http://yalemedicine.yale.edu/ym_wi07/faces.html |archivedate=2007-05-09 }}</ref><ref>{{Cite news |last=Pollack |first=Andrew |date=2011-01-05 |title=Taking DNA Sequencing to the Masses |language=en-US |work=The New York Times |url=https://www.nytimes.com/2011/01/05/health/05gene.html |access-date=2023-02-23 |issn=0362-4331}}</ref><ref name=":0">{{Cite web |last=Belli |first=Brita |date=2018-03-20 |title=Alumnus Rothberg enlists students to solve next healthcare challenges |url=https://news.yale.edu/2018/03/20/alumnus-rothberg-enlists-students-solve-next-healthcare-challenges |access-date=2023-06-20 |website=YaleNews |language=en}}</ref><ref>{{Cite news |last=Pollack |first=Andrew |date=2011-01-05 |title=Taking DNA Sequencing to the Masses |language=en-US |work=The New York Times |url=https://www.nytimes.com/2011/01/05/health/05gene.html |access-date=2023-06-20 |issn=0362-4331}}</ref> 

Located in Guilford, Connecticut, the organization was responsible for the CommunityTSC [[Distributed computing|distributed computing]] project.

Dr. Rothberg graduated from [[Organization:Yale University|Yale University]] in 1991.<ref name=":0" /> 

==CommunityTSC==
'''CommunityTSC Drug Design Optimization Lab (D2OL)''' was a [[Distributed computing|distributed computing]] project developed by the Institute to test drug candidates interaction with a target molecule that is essential to the spread of the disease under scrutiny. By evaluating the energy level released by binding a small molecule drug candidate to the surface of a larger Target molecule (D2OL) determines the fitness of the particular candidate to a region of the Target structure known as the Active Site. This process is referred to as docking the drug candidate to the target. D2OL ended on April 15, 2009.

==References==
{{Reflist|2}}

==External links==
*[http://www.childhooddiseases.org/ Rothberg Institute website]


[[Category:Distributed computing projects]]



{{Sourceattribution|Rothberg Institute for Childhood Diseases}}